Stable Amlodipine Oral Liquid Formulations for Hypertension and CAD Treatment

USPTO published patent application US20260097025A1 for stable amlodipine oral liquid formulations containing amlodipine for hypertension and Coronary Artery Disease treatment. The application includes claims to formulation compositions (A61K 31/4422, A61K 9/08, A61K 47/02, A61K 47/12, A61K 47/26, A61K 47/34, A61K 47/38) and methods of using the formulations for treating cardiovascular conditions.

Pharmaceutical companies developing cardiovascular drug formulations should monitor this application to assess potential freedom-to-operate implications or licensing opportunities. Patent applicants and patent practitioners should track prosecution for claim scope developments. The published application does not yet grant patent rights and remains subject to examination.